Skip to main content

Clinical Trials Using Labyrinthin Peptide Vaccine LabVax 3(22)-23

Review the clinical trials studying labyrinthin peptide vaccine labvax 3(22)-23 on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-1 of 1

A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF alone or in Combination with Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California